Sun Shukai, Wang Peng
Department of Neurosurgery, The Second Affiliated Hospital of Air Force Medical University Xi'an 710000, Shaanxi, China.
Am J Transl Res. 2025 Apr 15;17(4):3171-3178. doi: 10.62347/MWIS6762. eCollection 2025.
To investigate the expression of serum response factor (SRF) in glioma patients and its association with microvessel density (MVD) and postoperative recurrence.
This retrospective study included 100 glioma patients who underwent surgery at the Second Affiliated Hospital of Air Force Medical University between January 2021 and March 2024. Glioma specimens were collected to assess MVD. Meanwhile, preoperative serum samples were analyzed to measure SRF levels. The associations between SRF, MVD, and postoperative recurrence were analyzed. The diagnostic value of SRF and MVD for glioma progression and their predictive potential for postoperative recurrence were evaluated using receiver operating characteristic (ROC) curves. Univariate and multivariate analyses were conducted to identify independent risk factors for postoperative recurrence in glioma patients.
Serum levels of SRF and MVD were significantly higher in high-grade glioma patients than those in low-grade glioma patients. The area under the curve (AUC) for SRF in diagnosing glioma progression was 0.716, while that for MVD was 0.693; however, the combined use of SRF and MVD improved the AUC to 0.760. In glioma, SRF and MVD levels were not correlated with gender, tumor size, or age ( > 0.05), but were significantly correlated with lymph node metastasis ( < 0.05). There was a positive correlation between SRF and MVD levels in glioma patients ( < 0.05). Patients with recurrent gliomas exhibited significantly higher SRF and MVD levels than those without recurrence ( < 0.05). Logistic regression analysis identified lymph node metastasis, SRF, and MVD as independent risk factors for glioma recurrence ( < 0.05). The AUC for predicting postoperative recurrence was 0.676 for SRF and 0.730 for MVD. When combined, the AUC increased to 0.782.
SRF is highly expressed in high-grade glioma and is positively correlated with MVD. It is closely associated with postoperative recurrence and may serve as a potential biomarker for glioma progression and recurrence prediction.
探讨血清反应因子（SRF）在胶质瘤患者中的表达及其与微血管密度（MVD）和术后复发的关系。
本回顾性研究纳入了2021年1月至2024年3月在空军军医大学第二附属医院接受手术的100例胶质瘤患者。收集胶质瘤标本以评估MVD。同时，分析术前血清样本以测定SRF水平。分析SRF、MVD与术后复发之间的关系。使用受试者工作特征（ROC）曲线评估SRF和MVD对胶质瘤进展的诊断价值及其对术后复发的预测潜力。进行单因素和多因素分析以确定胶质瘤患者术后复发的独立危险因素。
高级别胶质瘤患者的血清SRF水平和MVD显著高于低级别胶质瘤患者。SRF诊断胶质瘤进展的曲线下面积（AUC）为0.716，而MVD为0.693；然而，联合使用SRF和MVD可将AUC提高至0.760。在胶质瘤中，SRF和MVD水平与性别、肿瘤大小或年龄无关（>0.05），但与淋巴结转移显著相关（<0.05）。胶质瘤患者的SRF和MVD水平呈正相关（<0.05）。复发性胶质瘤患者的SRF和MVD水平显著高于未复发患者（<0.05）。Logistic回归分析确定淋巴结转移、SRF和MVD为胶质瘤复发的独立危险因素（<0.05）。SRF预测术后复发的AUC为0.676，MVD为0.730。联合使用时，AUC增至0.782。
SRF在高级别胶质瘤中高表达，与MVD呈正相关。它与术后复发密切相关，可能作为胶质瘤进展和复发预测的潜在生物标志物。
